1 week ago
Mankind Pharma Signs China Deal for Two Insulin Products
Mankind Pharma has made a deal with a Chinese company to sell two insulin treatments in India.
The treatments are Insulin Degludec and a combination of Insulin Degludec and Insulin Aspart.
Both medicines are injectable treatments for diabetes care.
Insulin Degludec works for a long time, while Insulin Aspart works more quickly.
The deal gives Indian patients more diabetes-treatment options.
It is part of Mankind Pharma’s plan to bring medicines from other countries to India.
The company says its large network can help distribute the products.
Mankind Pharma also wants to grow its business in long-term treatments such as diabetes care.
Mankind Pharma signed an exclusive India licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical.
The deal covers Insulin Degludec and a combination of Insulin Degludec and Insulin Aspart.
Mankind Pharma will commercialise both injectable treatments in India.
The agreement expands the company’s injectable diabetes portfolio and chronic-therapy presence.
Mankind Pharma has more than 18,500 field professionals, 32 manufacturing facilities and seven research centres in India.
- Who
- Mankind Pharma and China-based Chongqing Chenan Biopharmaceutical.
- What
- An exclusive India in-licensing and marketing agreement for two injectable insulin products.
- Where
- India, with Chongqing Chenan Biopharmaceutical based in China.
- When
- The agreement was announced on Thursday; the exact date was not specified.
- Why
- To expand Mankind Pharma’s injectable diabetes portfolio, increase its chronic-therapy presence and offer Indian patients additional treatment options.
Key facts
- Products
- Insulin Degludec and a combination of Insulin Degludec and Insulin Aspart
- Market
- India
- Agreement
- Exclusive in-licensing and marketing agreement
- Field force
- More than 18,500 professionals
- Doctor reach
- More than five lakh doctors across urban and rural areas
- Manufacturing
- 32 manufacturing facilities in India
- Research and development
- Seven centres supported by more than 740 scientists
Quotes
Atish Majumdar
Senior President for Sales and Marketing at Mankind Pharma
“China was emerging as a centre for innovative biopharmaceutical assets. The company remained focused on expanding its in‑licensing pipeline from China after its partnerships for Insulin Aspart and Insulin Degludec.”
freepressjournal.in
Sources
Related news
Lupin Reassesses GLP-1 Market as It Develops New Treatments
Argentina Moves to Lower Barriers for Indian Pharma Trade
Lupin Arm Licenses Yuvezzi Marketing Rights From Visus
Sun Pharma Trades Lower Drug Prices for US Tariff Relief
Faridabad Doctor Arrested in Alleged Illegal Cancer Drug Sale
China’s Weight-Loss Drug Market Attracts Big Pharma Advertising Push
India’s 7.8% Growth Broad-Based, but Jobs Remain Challenge
India Pursues Global Mineral Pacts to Secure Supply Chains
Nepal Plans New Landslide Warning System Along China Border
RBI Governor Meets US Fed Chief Kevin Warsh at G20
Tencent-Backed Enflame IPO Draws Massive Investor Demand
